CN105579067A - 糖胺聚糖的化合物、其制备方法及用途 - Google Patents

糖胺聚糖的化合物、其制备方法及用途 Download PDF

Info

Publication number
CN105579067A
CN105579067A CN201480052224.5A CN201480052224A CN105579067A CN 105579067 A CN105579067 A CN 105579067A CN 201480052224 A CN201480052224 A CN 201480052224A CN 105579067 A CN105579067 A CN 105579067A
Authority
CN
China
Prior art keywords
cancer
glycosaminoglycan
conjugate
carcinoma
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480052224.5A
Other languages
English (en)
Chinese (zh)
Inventor
林华阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Holy Stone Biotech Co Ltd
Original Assignee
Holy Stone Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holy Stone Biotech Co Ltd filed Critical Holy Stone Biotech Co Ltd
Priority to CN202110839923.6A priority Critical patent/CN113893354A/zh
Priority to CN202111195328.XA priority patent/CN114010796A/zh
Publication of CN105579067A publication Critical patent/CN105579067A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480052224.5A 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途 Pending CN105579067A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110839923.6A CN113893354A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN202111195328.XA CN114010796A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361871352P 2013-08-29 2013-08-29
US61/871,352 2013-08-29
US14/308,972 2014-06-19
US14/308,972 US9572832B2 (en) 2013-08-29 2014-06-19 Compound of glycosaminoglycan and its fabrication method as well as application
PCT/EP2014/063720 WO2015028172A1 (en) 2013-08-29 2014-06-27 Compound of glycosaminoglycan, preparation method and use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202111195328.XA Division CN114010796A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN202110839923.6A Division CN113893354A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
CN105579067A true CN105579067A (zh) 2016-05-11

Family

ID=52584073

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201480052224.5A Pending CN105579067A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN202111195328.XA Pending CN114010796A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN202110839923.6A Pending CN113893354A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN201480035816.6A Active CN105324132B (zh) 2013-08-29 2014-08-27 糖胺聚醣化合物及其医药组合物与用途
CN201910772055.7A Pending CN110590971A (zh) 2013-08-29 2014-08-27 糖胺聚醣化合物及其医药组合物与用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202111195328.XA Pending CN114010796A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN202110839923.6A Pending CN113893354A (zh) 2013-08-29 2014-06-27 糖胺聚糖的化合物、其制备方法及用途
CN201480035816.6A Active CN105324132B (zh) 2013-08-29 2014-08-27 糖胺聚醣化合物及其医药组合物与用途
CN201910772055.7A Pending CN110590971A (zh) 2013-08-29 2014-08-27 糖胺聚醣化合物及其医药组合物与用途

Country Status (18)

Country Link
US (7) US9572832B2 (https=)
EP (2) EP3038656B1 (https=)
JP (2) JP6404925B2 (https=)
KR (2) KR102283978B1 (https=)
CN (5) CN105579067A (https=)
AU (6) AU2014314536B2 (https=)
BR (2) BR112016004357B1 (https=)
CA (3) CA3133859C (https=)
DK (1) DK3038656T3 (https=)
EA (4) EA038422B1 (https=)
ES (2) ES2893329T3 (https=)
HU (1) HUE056434T2 (https=)
LT (1) LT3038656T (https=)
MY (1) MY180502A (https=)
PL (1) PL3038656T3 (https=)
PT (1) PT3038656T (https=)
TW (2) TWI526212B (https=)
WO (2) WO2015028172A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782906A (zh) * 2021-06-18 2023-09-19 爱禾公司 透明质酸复合物的用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
EA027663B1 (ru) * 2016-05-20 2017-08-31 Тютор С.А.С.И.Ф.И.А. Способ получения твёрдой лекарственной формы для перорального применения и твёрдая лекарственная форма для перорального применения, полученная согласно указанному способу
KR102719543B1 (ko) 2019-06-03 2024-10-17 아이홀 코포레이션 히알루로난 접합체 및 이의 용도
US11458204B2 (en) 2020-06-02 2022-10-04 Aihol Corporation Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
WO2021252513A1 (en) * 2020-06-08 2021-12-16 Aihol Corporation Uses of hyaluronan conjugate
CA3179897A1 (en) * 2020-07-15 2022-01-20 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
CN116726186A (zh) * 2022-03-11 2023-09-12 四川省医学科学院·四川省人民医院 药物递送系统及其在制备抗黑色素瘤药物中的应用
CN118843468A (zh) * 2022-08-05 2024-10-25 爱禾公司 透明质酸-尼美舒利复合物于治疗局部晚及或转移性肿瘤的用途
PL249385B1 (pl) * 2022-11-23 2026-04-07 Politechnika Śląska Prolek-glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie
WO2025122826A1 (en) * 2023-12-07 2025-06-12 University Of Montana Hyaluronic acid-nonsteroidal anti-inflammatory drug conjugates for treating inflammation-mediated pathologies
CN118831067A (zh) * 2024-07-18 2024-10-25 广东药科大学 一种载药纳米粒及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082963A1 (en) * 1998-05-20 2001-03-14 Chugai Seiyaku Kabushiki Kaisha Remedies for joint diseases bound to hyaluronic acid
CN1930190A (zh) * 2004-01-07 2007-03-14 生化学工业株式会社 透明质酸衍生物及含有其的药剂
WO2008134528A1 (en) * 2007-04-25 2008-11-06 Board Of Regents, The University Of Texas System Anti-cancer agent-hyaluronic acid conjugate compositions and methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
JPH0585942A (ja) * 1991-02-26 1993-04-06 Denki Kagaku Kogyo Kk インターフエロン−ヒアルロン酸及び／又はその塩の結合体
JPH0673103A (ja) * 1991-11-27 1994-03-15 Lignyte Co Ltd ヒアルロン酸高分子複合体及びその製造方法
WO1994009811A1 (en) 1992-10-30 1994-05-11 Duke University An adhesion molecule
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
EP1064011A1 (en) 1998-03-13 2001-01-03 EntreMed, Inc. Metastatin and hyaluronate binding proteins and methods of use
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
GB9902412D0 (en) * 1999-02-03 1999-03-24 Fermentech Med Ltd Process
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
JP4266571B2 (ja) * 2002-05-17 2009-05-20 生化学工業株式会社 脂質結合グリコサミノグリカンの製造法
EP1562627A4 (en) * 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
EP1564220A4 (en) * 2002-11-21 2010-03-17 Chugai Pharmaceutical Co Ltd RETARD-DRUG CARRIER
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
CN1946743B (zh) * 2004-03-05 2010-06-02 电气化学工业株式会社 透明质酸/甲氨蝶呤化合物
US8143391B2 (en) * 2004-09-07 2012-03-27 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
WO2009048280A2 (en) * 2007-10-09 2009-04-16 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
US20090170195A1 (en) * 2007-12-28 2009-07-02 Kent State University Curcumin-hyaluronan compounds
PT2355853T (pt) * 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
US8759322B2 (en) * 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
EP2411413B1 (en) * 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
US20120082717A1 (en) * 2009-06-05 2012-04-05 Snu R&Db Foundation Complex, multilayer using the same, and device coated with the multilayer
CA2777397C (en) * 2009-10-13 2017-08-29 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
WO2011057078A2 (en) * 2009-11-05 2011-05-12 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
CN101732728B (zh) * 2010-01-25 2012-11-14 中国药科大学 抗炎药物-多糖偶联物及其药物组合物的制备和应用
WO2011130476A2 (en) * 2010-04-16 2011-10-20 The Research Foundation Of State University Of New York Polymer-based therapeutic agents
US20110300150A1 (en) * 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
HUE033169T2 (en) * 2011-03-03 2017-11-28 Chugai Pharmaceutical Co Ltd Amino carboxylic acid modified hyaluronic acid derivative
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
WO2015005458A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082963A1 (en) * 1998-05-20 2001-03-14 Chugai Seiyaku Kabushiki Kaisha Remedies for joint diseases bound to hyaluronic acid
CN1930190A (zh) * 2004-01-07 2007-03-14 生化学工业株式会社 透明质酸衍生物及含有其的药剂
WO2008134528A1 (en) * 2007-04-25 2008-11-06 Board Of Regents, The University Of Texas System Anti-cancer agent-hyaluronic acid conjugate compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WM LIU ET AL.: ""Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs(IMiDS)"", 《BRITISH JOURNAL OF CANCER》 *
叶志中等: "《解读红斑狼疮》", 31 August 2003, 辽宁科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782906A (zh) * 2021-06-18 2023-09-19 爱禾公司 透明质酸复合物的用途

Also Published As

Publication number Publication date
CA3133859A1 (en) 2015-03-05
CA3133853A1 (en) 2015-03-05
TWI526212B (zh) 2016-03-21
EA201992518A2 (ru) 2020-03-31
BR112016004357A2 (https=) 2017-08-01
PL3038656T3 (pl) 2022-01-10
TWI577378B (zh) 2017-04-11
EP3038660A4 (en) 2017-05-03
US20240325435A1 (en) 2024-10-03
EP3038660A1 (en) 2016-07-06
EA034600B1 (ru) 2020-02-25
AU2014314536A1 (en) 2016-04-07
KR20160048905A (ko) 2016-05-04
AU2019201691A1 (en) 2019-04-04
ES2851973T3 (es) 2021-09-09
AU2019268085B2 (en) 2021-01-07
EP3038660B1 (en) 2020-12-23
HK1223291A1 (en) 2017-07-28
KR101790649B1 (ko) 2017-10-26
EA201992517A3 (ru) 2020-05-31
CN113893354A (zh) 2022-01-07
EA201992517A2 (ru) 2020-03-31
US20220111062A1 (en) 2022-04-14
US20240325434A1 (en) 2024-10-03
NZ718048A (en) 2024-10-25
BR112015032529B1 (pt) 2022-06-21
US20170151336A1 (en) 2017-06-01
DK3038656T3 (da) 2021-10-11
EA201992518A3 (ru) 2020-05-31
EA201690487A1 (ru) 2016-11-30
KR20160014690A (ko) 2016-02-11
BR112015032529A2 (pt) 2017-07-25
US10342878B2 (en) 2019-07-09
WO2015028172A1 (en) 2015-03-05
EA038422B1 (ru) 2021-08-26
JP2016529362A (ja) 2016-09-23
PT3038656T (pt) 2021-10-15
US20150065450A1 (en) 2015-03-05
CN105324132A (zh) 2016-02-10
US20240238329A9 (en) 2024-07-18
CN110590971A (zh) 2019-12-20
CN105324132B (zh) 2020-07-21
AU2014314536B2 (en) 2019-11-07
AU2019268087B2 (en) 2020-09-10
US11229665B2 (en) 2022-01-25
US9572832B2 (en) 2017-02-21
AU2014311302A1 (en) 2016-01-21
LT3038656T (lt) 2021-12-10
TW201509422A (zh) 2015-03-16
EP3038656A1 (en) 2016-07-06
JP2016525515A (ja) 2016-08-25
ES2893329T3 (es) 2022-02-08
HUE056434T2 (hu) 2022-02-28
EA038278B1 (ru) 2021-08-04
MY180502A (en) 2020-11-30
CA2921830C (en) 2022-03-08
CA3133853C (en) 2023-03-07
CA3133859C (en) 2023-03-14
CN114010796A (zh) 2022-02-08
US20150065446A1 (en) 2015-03-05
AU2019268087A1 (en) 2019-12-12
EA201501166A1 (ru) 2016-10-31
AU2019201691B2 (en) 2019-10-03
CA2921830A1 (en) 2015-03-05
AU2019268085A1 (en) 2019-12-12
JP6433494B2 (ja) 2019-02-06
JP6404925B2 (ja) 2018-10-17
HK1225993A1 (en) 2017-09-22
TW201509421A (zh) 2015-03-16
EA031285B1 (ru) 2018-12-28
US20190275164A1 (en) 2019-09-12
AU2017204619A1 (en) 2017-07-27
BR112016004357B1 (pt) 2022-09-27
EP3038656B1 (en) 2021-08-18
KR102283978B1 (ko) 2021-08-02
WO2015031425A1 (en) 2015-03-05
US12285441B2 (en) 2025-04-29

Similar Documents

Publication Publication Date Title
US12285441B2 (en) Uses of glycosaminoglycan conjugates
CA2722376C (en) Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
Brown The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs
Mero et al. Recent developments in hyaluronic acid-based nanomedicine
HK1225993B (en) Compound of glycosaminoglycan, preparation method and use thereof
파자나 Designing functional formulations of a taurocholate conjugated low molecular weight heparin derivative for targeting tumor angiogenesis and metastasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Lin Huayang

Inventor before: Lin Huayang

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160511